CRIZOTINIB
| Brand name | XALKORI |
|---|---|
| Active ingredient | CRIZOTINIB |
| Strength | 50MG |
| Dosage form | CAPSULE, PELLETS |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | September 2023 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 8217057 | November 2029 | substance |
| 7858643 | October 2029 | substance, product |
| 7825137 | May 2027 | use U-3403 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.